Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects

Jing Ma\textsuperscript{1,2}, Jessica Chang\textsuperscript{3}, Helen L. Checklin\textsuperscript{1,2}, Richard L. Young\textsuperscript{1,2,4}, Karen L. Jones\textsuperscript{1,2}, Michael Horowitz\textsuperscript{1,2,3}, and Christopher K. Rayner\textsuperscript{1,2*}

\textsuperscript{1}Discipline of Medicine, Royal Adelaide Hospital, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia
\textsuperscript{2}Centre of Clinical Research Excellence in Nutritional Physiology, Interventions and Outcomes, University of Adelaide, Adelaide, SA, Australia
\textsuperscript{3}Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
\textsuperscript{4}Nerve-Gut Research Laboratory, Hanson Institute, Royal Adelaide Hospital, Adelaide, SA, Australia

(Received 9 September 2009 – Revised 9 March 2010 – Accepted 10 March 2010 – First published online 27 April 2010)

It has been reported that the artificial sweetener, sucralose, stimulates glucose absorption in rodents by enhancing apical availability of the transporter GLUT2. We evaluated whether exposure of the proximal small intestine to sucralose affects glucose absorption and/or the glycaemic response to an intraduodenal (ID) glucose infusion in healthy human subjects. Ten healthy subjects were studied on two separate occasions in a single-blind, randomised order. Each subject received an ID infusion of sucralose (4 mM in 0.9% saline) or control (0.9% saline) at 4 ml/min for 150 min (T = 230 to 120 min). After 30 min (T = 0), glucose (25%) and its non-metabolised analogue, 3-O-methylglucose (3-OMG; 2.5%), were co-infused intraduodenally (T = 0–120 min; 4.2 kJ/min (1 kcal/min)). Blood was sampled at frequent intervals. Blood glucose, plasma glucagon-like peptide-1 (GLP-1) and serum 3-OMG concentrations increased during ID glucose/3-OMG infusion (P<0.005 for each). However, there were no differences in blood glucose, plasma GLP-1 or serum 3-OMG concentrations between sucralose and control infusions. In conclusion, sucralose does not appear to modify the rate of glucose absorption or the glycaemic or incretin response to ID glucose infusion when given acutely in healthy human subjects.

3-O-methylglucose: Sodium-dependent GLUT 1: GLUT 2: Glucagon-like peptide-1

The mechanisms by which the gut senses nutrients are unclear, and the ‘receptor’ for detecting luminal carbohydrates has, until recently, been elusive. Recent studies indicate the presence of G-protein-coupled taste receptors, T1R2 and T1R3, and their taste signal transduction partners, the G-protein gustducin and the transient receptor potential ion channel TRPM5, in the mucosa of the mouse and human gastrointestinal tract\textsuperscript{1,2}. These receptors, analogous to sweet taste receptors on the tongue, broadly respond to sugars and artificial sweeteners, and among several cell types, they appear to co-localise with glucagon-like peptide-1 (GLP-1)-secreting L cells\textsuperscript{3}.

It has been reported that the artificial sweetener, sucralose, stimulates the secretion of both GLP-1 and glucose-dependent insulinotropic polypeptide from the mouse enteroendocrine cell line GLUTag\textsuperscript{4}, and it stimulates GLP-1 secretion from the human L cell line NCI-H716\textsuperscript{3}, a response that is blocked by the sweet receptor antagonist, lactisole, and siRNA for α-gustducin\textsuperscript{4}. However, we recently demonstrated that sucralose, in two different loads, had no effect on GLP-1, glucose-dependent insulinotropic polypeptide or insulin secretion, and that it did not elicit any feedback response on gastric emptying in healthy human subjects\textsuperscript{5}. While this implies that artificial sweeteners may have no therapeutic benefit in the dietary management of diabetes, other than as a substitute for carbohydrates, it remains possible that sucralose affects small intestinal carbohydrate absorption as a result of its interaction with the sweet taste receptors.

Glucose is absorbed from the small intestine through both the Na-dependent GLUT 1 (SGLT1) and the facilitative transporter GLUT2\textsuperscript{6}. Supplementation of the diet with sucralose increases the expression of SGLT1 in the enterocytes of wild-type mice, but not in mice deficient in T1R3 or α-gustducin\textsuperscript{4}. The presence of sucralose enhances insertion of GLUT2 into the apical region of the enterocytes, and thus, stimulates glucose absorption in rats\textsuperscript{7,8}. For example, sucralose administration doubled the level of GLUT2 protein.
detected in apical membrane vesicles in response to low luminal glucose concentrations (20 mM)\(^2\), and the maximum rate of glucose absorption was reached after 20 min of exposure to sucralose in vivo\(^3\). This raises the question as to whether the combination of an artificial sweetener with a carbohydrate could have a synergistic effect on glucose absorption in human subjects. The notion that consuming artificial sweeteners together with carbohydrates could enhance glucose absorption and therefore elevate postprandial blood glucose concentrations is of fundamental clinical importance.

The aim of the present study was to evaluate whether exposure of the proximal small intestine to sucralose affects the subsequent response to glucose in terms of the rate of glucose absorption and the glycaemic response.

**Study plan and design**

**Subjects**

Ten healthy subjects (eight males and two females; age 27 (SD 2) years and BMI 23.4 (SD 0.8) kg/m\(^2\)) were studied in the follicular phase of the menstrual cycle to avoid any potential effects of the menstrual cycle on the occurrence of gastrointestinal symptoms, or significant previous surgery. Each subject provided written informed consent before participating, and the study was approved by the Royal Adelaide Hospital Research Ethics Committee.

**Protocol**

All the participants attended the Discipline of Medicine at the Royal Adelaide Hospital at approximately 08.30 hours after an overnight fast (14 h for solids and 12 h for liquids) on two occasions, which were separated by at least 3 d. The women were studied in the follicular phase of the menstrual cycle to avoid any potential effects of the menstrual cycle on the upper gastrointestinal function\(^4\).

On each study day, a multilumen silicone catheter (external diameter 4 mm) was introduced into the stomach through an anaesthetised nostril, and was allowed to pass into the duodenum by peristalsis. This catheter incorporated a side hole to deliver infusions into the proximal duodenum; its position was monitored continuously during the study by measurement of the transmucosal potential difference, from two other saline-perfused side holes on either side of the pylorus, using established criteria (antral potential < −20 mV, duodenal potential > −15 mV and difference >15 mV)\(^5\). This required the insertion of a 20G saline-filled cannula subcutaneously into the forearm as a reference. When the catheter was positioned correctly, an intravenous cannula was inserted into a forearm vein for subsequent blood sampling.

After the baseline blood samples were collected (\(T = 30\)), an intraduodenal (ID) infusion of sucralose (960 mg made up to 600 ml with 0.9% saline (sucralose concentration 4 mM)) or 600 ml of 0.9% saline alone as a control was commenced and continued at a rate of 4 ml/min for 150 min (\(T = 30\) to 120 min). At \(T = 0\) min, an ID infusion of glucose solution (30 g glucose together with 3 g 3-O-methylglucose (3-OMG), Sigma-Aldrich, St Louis, MO, USA) made up to a total volume of 120 ml with water (approximately 1390 mM glucose) was also commenced via the same channel in the catheter, and was continued at a rate of 1 ml/min (\(= 4.2\) kJ/min (1 kcal/min)) for 120 min (\(T = 0\)–120 min). The final concentration of glucose that was infused was approximately 280 mM due to dilution with co-infused saline/sucralose.

Venous blood samples (approximately 20 ml) were collected immediately before the ID infusion was commenced, and at \(T = −15, 0, 5, 10, 20, 30, 40, 60, 90\) and 120 min. Blood glucose concentrations were measured immediately using a glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). The remainder of each blood sample was distributed into a serum tube and a tube containing EDTA and 0.056 mg aprotinin (Trasylol; Bayer Australia, Pymble, NSW, Australia) per litre of blood, stored on ice and centrifuged at 3200 rpm for 15 min. Serum and plasma were separated, and the samples were stored at −70°C for subsequent analysis. 3-OMG was extracted from serum by protein precipitation extraction with methanol under monitoring using an API3000TM LC/MS/MS mass spectrometer (Applied Biosystems, Foster City, CA, USA; MDS Sciex, ON, Canada). The range of detection was 2000–200 000 ng/ml when using a sample volume of 100 μl. 3-OMG is an analogue of glucose that is absorbed from the gut in the same way as glucose but not metabolised; therefore, serum concentrations represent an index of glucose absorption\(^6\). Plasma total GLP-1 concentrations were measured by RIA (GLPIT-36HK; Linco Research, St Charles, MO, USA); the intra-assay CV was 6.7% and inter-assay CV was 7.8%, and the sensitivity was 3 pmol/l.

**Statistical analysis**

Repeated measures ANOVA (SuperANOVA; Abacus Concepts, Berkeley, CA, USA) was used to analyse the blood glucose, plasma GLP-1 and serum 3-OMG concentrations with both treatment and time as factors. Statistical significance was accepted as \(P < 0.05\), and data are presented as mean values with their standard errors.

**Results**

All the subjects tolerated the study well.

**Blood glucose concentrations**

There was no difference in baseline glucose concentrations between the two study days. Blood glucose concentrations also did not differ over \(T = −30\) to 0 min during infusions of sucralose or saline. There was a rise in blood glucose concentration after the ID glucose infusion was begun, which was evident from \(T = 20\) min (\(P < 0.001\)) on both the days. There were no differences between blood glucose concentrations in the subjects receiving sucralose or saline infusions (Fig. 1(a)).

**Plasma glucagon-like peptide-1 concentrations**

There was no difference in baseline GLP-1 concentrations between the two study days. GLP-1 concentrations did not differ over \(T = −30\) to 0 min during infusions of sucralose or saline, but they increased transiently on both the days
Hence, consuming artificial sweeteners can influence intestinal glucose absorption by inserting GLUT2 into the apical membrane (7). Therefore, if apical GLUT2 insertion occurred, the potential acute interaction of intraluminal sucralose with glucose in relation to small intestinal glucose absorption and blood glucose concentrations in apparently healthy human subjects. The negative outcome is consistent with previous studies that showed no effect of sucralose supplementation on glycemic response in patients with diabetes (16,17).

In the present study, we infused sucralose and glucose directly into the duodenum, rather than administering them orally, in order to regulate precisely the exposure of the small intestine to these substances. In studies where sucralose stimulated T1R2 + T1R3, resulting in apical insertion of GLUT2, the concentration of sucralose was 1 mM (7). Thus, 4 mM sucralose should have been sufficient to obtain a response. We used a glucose concentration (approximately 280 mM) which would itself be expected to induce apical GLUT2 insertion maximally (7), but this process would have taken about 20 min (8). If prior exposure to sucralose did indeed modulate apical GLUT2, a difference in glucose absorption should have been evident early in the ID glucose infusion.

Species differences are likely to account for the lack of effect of sucralose in human subjects. It has been reported that there is much lower duodenal expression of GLUT2 in human subjects than in rats and mice, while expression of SGLT1 is much greater in human subjects (18). Therefore, SGLT1 is likely to play a dominant role in glucose absorption in the human small intestine. Mutation of SGLT1 in human subjects results in glucose–galactose malabsorption, whereas absorption of these sugars is not disrupted by mutations of GLUT2 (19). Moreover, if apical GLUT2 insertion occurred in human subjects, one might expect this to ameliorate the effects of SGLT1 mutation and allow glucose to be tolerated in this disorder, but this appears not to be the case (15). Supplementation of a low-sugar chow with sucralose for 2 weeks in mice has been reported to increase SGLT1 protein and mRNA expression (4). Thus, it is still possible that prolonged exposure to sucralose (substantially for more than 20 min) could increase small intestinal glucose absorption in human subjects, although this would need to be evaluated in a separate study.

In conclusion, we have demonstrated that acute ID administration of sucralose does not enhance the absorption of glucose from the small intestine or increase blood glucose or plasma GLP-1 concentrations in healthy human subjects.
Acknowledgements

The present study was supported by awards from the Sylvia and Charles Viertel Charitable Foundation and the Faculty of Health Sciences, University of Adelaide, to C. K. R., and by the National Health and Medical Research Council of Australia. We wish to thank Tate & Lyle, Inc., Decatur, IL, USA, for supplying the sucralose used in the present study. The contributions of each author are as follows: J. M. contributed to study design, data collection and analysis, initial manuscript drafting and revision; J. C. contributed to data collection and analysis, and manuscript review; H. L. C. contributed to data collection and analysis, and manuscript review; R. L. Y. contributed to study design and manuscript review; C. K. R. conceived study design and manuscript review; M. H. contributed to study design and manuscript review; K. L. J. contributed to data collection and analysis, and manuscript review; C. E. contributed to data collection and analysis, initial manuscript drafting and analysis, and manuscript review; M. H. contributed to study design and manuscript review; C. K. R. conceived the study, and contributed to data analysis and manuscript review. No author has any conflict of interest to declare.

References